Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albertsons Companies Inc (ACI) vs Eli Lilly And Co (LLY) Price & Performance

Albertsons Companies IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Albertsons Companies Inc vs Eli Lilly And Co — how do they compare? Albertsons Companies Inc trades at $12.05 (market cap $5.95B), while Eli Lilly And Co trades at $1,213.62 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 181.5× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.

ACILLY
Market Cap
$5.95B$1.08T
Sector
Consumer StaplesHealth
52-Week High
$19.74$1.24K
52-Week Low
$11.03$639.43
Enterprise Value
$21.35B$1.13T
Dividend Yield
5.55%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albertsons Companies Inc

Albertsons (ACI) trades at $12.13, up 1.0% on the day, but remains near multi-year lows after a sharp 22% drop following Q2 2026 earnings miss and lowered guidance. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $80.39B in 2025, but net income margin compressed to 0.08%, reflecting margin pressure. Recent news highlights CEO and CFO stock purchases, AI initiatives like the Safeway ChatGPT plugin, and ongoing shareholder litigation investigations.

The outlook is cautious; ACI presents a deep-value case with low P/S of 0.08, but execution risks and weak profitability trends pose challenges. Analyst consensus is mixed with a $13.20 price target. Key risks include competitive grocery margins, litigation overhangs, and macroeconomic headwinds affecting consumer spending.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Albertsons Companies Inc

Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.

Read more on ACI

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY